Several tumor suppressor genes and oncogenes have been shown to be mutated in pancreatic cancer; for example, KRAS2, TP53, SMAD4, and other tumor-associated genes have been demonstrated to contribute to the pathogenesis of pancreatic cancer by promoting the expression of downstream genes and disrupting the cell cycle [3]. This evidence concerns the gene KRAS and familial pancreatic carcinoma.